Authors
David Wilson, Karen Copeland, Lindsey Mette, Meenakshi Khare, Matt Polak, Jorge Marques Signes, Tim Skelton
Published in
Alzheimer's & dementia (Amsterdam, Netherlands). Volume 18. Issue 3. Pages e70420. Epub Jul 09, 2026.
Abstract
Alzheimer's blood-based biomarker (BBM) tests using single biomarkers or ratios are well characterized, but head-to-head comparisons of multi-analyte algorithmic tests on shared cohorts are lacking. We compared a five-biomarker algorithmic immunoassay (LucentAD Complete) with an algorithmic immunoprecipitation mass-spectrometry (IP-MS) benchmark on a shared plasma cohort.
Symptomatic individuals (n = 192) with longitudinal samples from Alzheimer's Disease Neuroimaging Initiative (ADNI) were analyzed versus amyloid positron emission tomography (PET). Cross-sectional (n = 115) and longitudinal (n = 179; 12-year span) cohorts representing disease progression were used.
The immunoassay amyloid risk score demonstrated a 0.94 area under the curve (AUC) and 92%-93% accuracy, achieving performance parity with IP-MS metrics on shared samples. The two-cutoff design yielded an intermediate zone of 10.4%-12.8%.
These results establish diagnostic parity between algorithmic immunoassay and algorithmic IP-MS assay. In addition, providing individual biomarker results alongside a validated risk score offers a more granular foundation for comprehensive management than amyloid status alone, supporting premium reimbursement for multi-analyte algorithmic BBMs in clinical practice.
PMID:
42434607
Bibliographic data and abstract were imported from PubMed on 11 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 14
- Comments 0